PROBIOTIX HEALTH CHOLBIOME®X3 SHORTLISTED IN THE NUTRAINGREDIENTS AWARDS 2020
Leading European industry publication NutraIngredients has named CholBiome®X3, a pioneering cholesterol management product from ProBiotix Health, as a finalist for the ‘Editors Award for Functional Food Innovation’ category of its 2020 awards.
ProBiotix Health, a subsidiary of OptiBiotix Health PLC (‘OptiBiotix’), is part of the leading life sciences business which develops compounds to tackle obesity, cardiovascular disease and diabetes. The company, which is built on a foundation of scientific principles, developed CholBiomeX3 as a natural and holistic non-pharmaceutical alternative to promote heart wellness.
Steve Prescott, CEO of ProBiotix Health, commented: “We are absolutely thrilled to be named as a finalist in this year’s NutraIngredients Awards. CholBiomeX3 is an innovative and science-backed solution that transforms the way cardiovascular and physiological wellbeing is approached. By using a unique tri-layer combination of ingredients, including our patented probiotic strain LPLDL®, CholBiomeX3 offers a scientifically backed approach to lower harmful cholesterol, reduce blood pressure and deliver real heart health benefits.”
CholBiomeX3 combines three key ingredients – Lactobacillus Plantarum LPLDL, Vitamin B3 and red yeast rice which is rich in Monacolin K – to deliver three mechanisms of action to improve general health and wellbeing. By using the main ingredient found in CholBiomeX3, LPLDL has demonstrated its efficacy through parallel, double-blind and placebo-controlled human studies, reducing harmful LDL cholesterol by 13.9% and increasing good HDL cholesterol by 4.5%.
The NutraIngredients Awards reward true innovation, long-term market success and cutting-edge research in today’s nutraceutical industry. For the first time, this year’s award ceremony will be hosted online in light of the ongoing public health emergency, with the winner’s announced on Wednesday 13th May.